ImPact Biotech Reports Encouraging Early Clinical Results From Phase 1 Study of Padeliporfin VTP in Pancreatic Cancer, with Seven Previously Unresectable Patients Undergoing Surgical Resection Following Treatment

ImPact Biotech announced positive Phase 1 results for Padeliporfin VTP in locally advanced pancreatic cancer, with 75% of 12 treated patients undergoing or scheduled for surgical resection. Seven patients achieved successful resection, with over 55% achieving R0 resections (negative margins). The therapy demonstrated a favorable safety profile across escalating light-dose cohorts, supporting advancement to Phase 1 Part B and regulatory discussions.